Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways

Journal of Virology

Volumn 83, Issue 22, 2009, Pages 11440-11446

  Fransen, Signe ^a   Gupta, Soumi ^a   Danovich, Robert ^b,c   Hazuda, Daria ^b   Miller, Michael ^b   Witmer, Marc ^b   Petropoulos, Christos J ^a   Huang, Wei ^a  

^a MONOGRAM BIOSCIENCES   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Percepticore LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE; RALTEGRAVIR;

ANTIVIRAL RESISTANCE; ARTICLE; CLONE; EMBRYO; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VIRUS GENOME; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MUTAGENESIS, SITE-DIRECTED; PYRROLIDINONES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 70350666377     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01168-09     Document Type: Article

References (27)

1. Asante-Appiah, E., and A. M. Skalka. 1999. HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv. Virus Res. 52:351-369.
2. Bushman, F. D., and R. Craigie. 1991. Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA. Proc. Natl. Acad. Sci. USA 88:1339-1343.
3. Bushman, F. D., T. Fujiwara, and R. Craigie. 1990. Retroviral DNA integration directed by HIV integration protein in vitro. Science 249:1555-1558. (Pubitemid 20341932)
4. Charpentier, C., M. Karmochkine, D. Laureillard, P. Tisserand, L. Belec, L. Weiss, A. Si-Mohamed, and C. Piketty. 2008. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. HIV Med. 9:765-770.
5. Cooper, D. A., R. T. Steigbigel, J. M. Gatell, J. K. Rockstroh, C. Katlama, P. Yeni, A. Lazzarin, B. Clotet, P. N. Kumar, J. E. Eron, M. Schechter, M. Markowitz, M. R. Loutfy, J. L. Lennox, J. Zhao, J. Chen, D. M. Ryan, R. R. Rhodes, J. A. Killar, L. R. Gilde, K. M. Strohmaier, A. R. Meibohm, M. D. Miller, D. J. Hazuda, M. L. Nessly, M. J. DiNubile, R. D. Isaacs, H. Teppler, and B. Y. Nguyen. 2008. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med. 359:355-365.
6. Da Silva, D., I. Pellegrin, G. Anies, D. Breith, L. Wittkop, P. Morlat, M. Dupon, D. Neau, J. L. Pellegrin, H. Fleury, and B. Masquelier. 2008. Mutational patterns in the HIV-1 integrase related to virological failures on raltegravir-containing regimens. Antivir. Ther. 13:A14.
7. DeJesus, E., D. Berger, M. Markowitz, C. Cohen, T. Hawkins, P. Ruane, R. Elion, C. Farthing, L. Zhong, A. K. Cheng, D. McColl, and B. P. Kearney. 2006. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J. Acquir. Immune Defic. Syndr. 43:1-5.
8. Engelman, A., F. D. Bushman, and R. Craigie. 1993. Identification of discrete functional domains of HIV-1 integrase and their organization within an active multimeric complex. EMBO J. 12:3269-3275. (Pubitemid 23232758)
9. Engelman, A., K. Mizuuchi, and R. Craigie. 1991. HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell 67:1211-1221. (Pubitemid 121001533)
10. Esposito, D., and R. Craigie. 1999. HIV integrase structure and function. Adv. Virus Res. 52:319-333.
11. Evering, T. H., and M. Markowitz. 2007. Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1. Drugs Today (Barcelona) 43: 865-877.
12. Fikkert, V., B. Van Maele, J. Vercammen, A. Hantson, B. Van Remoortel, M. Michiels, C. Gurnari, C. Pannecouque, M. De Maeyer, Y. Engelborghs, E. De Clercq, Z. Debyser, and M. Witvrouw. 2003. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J. Virol. 77:11459-11470. (Pubitemid 37271644)
13. Goethals, O., R. Clayton, M. Van Ginderen, I. Vereycken, E. Wagemans, P. Geluykens, K. Dockx, R. Strijbos, V. Smits, A. Vos, G. Meersseman, D. Jochmans, K. Vermeire, D. Schols, S. Hallenberger, and K. Hertogs. 2008. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J. Virol. 82:10366-10374. (Pubitemid 352691161)
14. Goodman, D., R. Hluhanich, J. Waters, N. Margot, S. Fransen, S. Gupta, W. Huang, N. T. Parkin, K. Borroro-Esoda, E. Svarovskaia, M. Miller, and D. McColl. 2008. Integrase inhibitor resistance involves complex interactions among primary and secondary resistance mutations: a novel mutation L68V/I associates with E92Q and increases resistance. Antivir. Ther. 13:A15.
15. Greenberg, M. L., and N. Cammack. 2004. Resistance to enfuvirtide, the first HIV fusion inhibitor. J. Antimicrob. Chemother. 54:333-340.
16. Gulick, R. M., J. Lalezari, J. Goodrich, N. Clumeck, E. DeJesus, A. Horban, J. Nadler, B. Clotet, A. Karlsson, M. Wohlfeiler, J. B. Montana, M. McHale, J. Sullivan, C. Ridgway, S. Felstead, M. W. Dunne, E. van der Ryst, and H. Mayer. 2008. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359:1429-1441.
17. Hazuda, D. J., N. J. Anthony, R. P. Gomez, S. M. Jolly, J. S. Wai, L. Zhuang, T. E. Fisher, M. Embrey, J. P. Guare, Jr., M. S. Egbertson, J. P. Vacca, J. R. Huff, P. J. Felock, M. V. Witmer, K. A. Stillmock, R. Danovich, J. Grobler, M. D. Miller, A. S. Espeseth, L. Jin, I. W. Chen, J. H. Lin, K. Kassahun, J. D. Ellis, B. K. Wong, W. Xu, P. G. Pearson, W. A. Schleif, R. Cortese, E. Emini, V. Summa, M. K. Holloway, and S. D. Young. 2004. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc. Natl. Acad. Sci. USA 101:11233-11238.
18. Hazuda, D. J., P. Felock, M. Witmer, A. Wolfe, K. Stillmock, J. A. Grobler, A. Espeseth, L. Gabryelski, W. Schleif, C. Blau, and M. D. Miller. 2000. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287:646-650.
19. Lee, D. J., and W. E. Robinson, Jr. 2006. Preliminary mapping of a putative inhibitor-binding pocket for human immunodeficiency virus type 1 integrase inhibitors. Antimicrob. Agents Chemother. 50:134-142.
20. Malet, I., O. Delelis, M. A. Valantin, B. Montes, C. Soulie, M. Wirden, L. Tchertanov, G. Peytavin, J. Reynes, J. F. Mouscadet, C. Katlama, V. Calvez, and A. G. Marcelin. 2008. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob. Agents Chemother. 52:1351-1358.
21. Miller, M. D., R. M. Danovich, Y. K. E., M. Witmer, J. Zhao, C. Harvey, B.-Y. Nguyen, and D. J. Hazuda. 2008. Longitudinal analysis of resistance to the HIV-1 integrase inhibitor raltegravir: results from P005 a Phase II study in treatment-experienced patients. Antivir. Ther. 13:A8.
22. Nakahara, K., C. Wakasa-Morimoto, M. Kobayashi, S. Miki, T. Noshi, T. Seki, M. Kanamori-Koyama, S. Kawauchi, A. Suyama, T. Fujishita, T. Yoshinaga, E. P. Garvey, B. A. Johns, S. A. Foster, M. R. Underwood, A. Sato, and T. Fujiwara. 2009. Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics. Antivir. Res. 81:141-146.
23. Petropoulos, C. J., N. T. Parkin, K. L. Limoli, Y. S. Lie, T. Wrin, W. Huang, H. Tian, D. Smith, G. A. Winslow, D. J. Capon, and J. M. Whitcomb. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920-928.
24. Pluymers, W., G. Pais, B. Van Maele, C. Pannecouque, V. Fikkert, T. R. Burke, Jr., E. De Clercq, M. Witvrouw, N. Neamati, and Z. Debyser. 2002. Inhibition of human immunodeficiency virus type 1 integration by diketo derivatives. Antimicrob. Agents Chemother. 46:3292-3297.
25. Rhee, S. Y., T. F. Liu, M. Kiuchi, R. Zioni, R. J. Gifford, S. P. Holmes, and R. W. Shafer. 2008. Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. Retrovirology 5:74.
26. Witmer, M., and R. Danovich. 2009. Selection and analysis of HIV-1 integrase strand transfer inhibitor resistant mutant viruses. Methods 47: 277-282.
27. Zhuang, L., J. S. Wai, M. W. Embrey, T. E. Fisher, M. S. Egbertson, L. S. Payne, J. P. Guare, Jr., J. P. Vacca, D. J. Hazuda, P. J. Felock, A. L. Wolfe, K. A. Stillmock, M. V. Witmer, G. Moyer, W. A. Schleif, L. J. Gabryelski, Y. M. Leonard, J. J. Lynch, Jr., S. R. Michelson, and S. D. Young. 2003. Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. J. Med. Chem. 46:453-456.